FibroGen to Participate in Upcoming Investor Conferences
May 07, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America...
FibroGen Reports First Quarter 2024 Financial Results
May 06, 2024 16:02 ET
|
FibroGen, Inc.
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in...
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024 16:06 ET
|
FibroGen, Inc.
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate...